Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Genitourinary 1Dermatologic 1

Conditions

Melanoma 53Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 32Neoplasms 29Neoplasm Metastasis 24Colorectal Neoplasms 21Carcinoma, Hepatocellular 21Squamous Cell Carcinoma of Head and Neck 18Stomach Neoplasms 16Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Small Cell Lung Carcinoma 11Pancreatic Neoplasms 11Lung Neoplasms 11Hodgkin Disease 11Carcinoma, Transitional Cell 10Advanced Cancer 9Sarcoma 8Recurrence 8Head and Neck Neoplasms 8Solid Tumor 7Prostatic Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Carcinoma, Merkel Cell 6Breast Neoplasms 6Mesothelioma 5Glioblastoma 5

Interventions

Ipilimumab 5pembrolizumab 3Nivolumab 3Paclitaxel 2Oxaliplatin 2Doxorubicin 2Capecitabine 2CTLA-4 Antigen 2tremelimumab 1trastuzumab deruxtecan 1tebentafusp 1spartalizumab 1lenvatinib 1eribulin 1envafolimab 1durvalumab 1Vemurafenib 1Surgical Procedures, Operative 1Radiotherapy 1Radiosurgery 1Radiation 1Leucovorin 1Immunotherapy 1Fluorouracil 1Docetaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Diabetes Mellitus, Insulin-Dependent, 12 × Nivolumab × Clear all
NCT03639714 2023-09-13

A Study of a Personalized Neoantigen Cancer Vaccine

Gritstone bio, Inc.

Phase 1/2 Completed
29 enrolled
GastrointestinalGenitourinaryThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms

NCT03953235 2023-09-13

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Gritstone bio, Inc.

Phase 1/2 Completed
39 enrolled
GastrointestinalThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03354962 2020-12-04

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Institut Claudius Regaud

Phase 1/2 Terminated
6 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡